Am J Cardiol. 1985 Nov 22;56(14):15G-22G.
After 15 days there were 142 deaths in the placebo group (4.9%) and 123 deaths in the metoprolol group (4.3%), a difference of 13% (p = 0.29). The 95% confidence limits for the relative effect of metoprolol ranged from an 8% excess (-8%) to a 33% reduction (+33%) in mortality. There was generally a lower mortality rate for metoprolol-treated patients in most subgroups and a consistent tendency for a more pronounced difference between the treatment groups in those subgroups with a placebo mortality rate higher than the average for all placebo patients. Most deaths were cardiac and occurred among patients who developed a definite myocardial infarction (97%) and most of these had a Q-wave infarction (83%). Using a simple model, the placebo mortality was found to increase with increasing number of 8 risk predictors defined from prestudy experience, from 0% in patients with no risk predictors to 11.6% in patients with any 5 or more of these risk factors. Similarly, there was an increase in the difference between the treatment groups in favor of metoprolol with increasing number of placebo risk factors. Metoprolol had no apparent effect in a low-mortality risk group (less than or equal to 2 risk factors), but there was a difference in mortality of 29% in favor of metoprolol in a high-risk group (greater than or equal to 3 risk factors) comprising one-third of the trial population.(ABSTRACT TRUNCATED AT 250 WORDS)
15天后，安慰剂组有142例死亡（4.9%），美托洛尔组有123例死亡（4.3%），差异为13%（p = 0.29）。美托洛尔相对疗效的95%置信区间为死亡率增加8%（-8%）至降低33%（+33%）。在大多数亚组中，美托洛尔治疗的患者死亡率通常较低，在安慰剂死亡率高于所有安慰剂患者平均水平的亚组中，治疗组之间的差异有更明显的一致趋势。大多数死亡为心脏性死亡，发生在发生明确心肌梗死的患者中（97%），其中大多数为Q波梗死（83%）。使用一个简单模型发现，根据研究前经验定义的8个风险预测因素数量增加时，安慰剂死亡率随之增加，从无风险预测因素的患者中的0%增至有5个或更多这些风险因素的患者中的11.6%。同样，随着安慰剂风险因素数量增加，治疗组之间有利于美托洛尔的差异也在增加。美托洛尔在低死亡风险组（小于或等于2个风险因素）中无明显效果，但在占试验人群三分之一的高风险组（大于或等于3个风险因素）中，美托洛尔使死亡率降低29%。（摘要截选至250字）
